Skip Therapeutics
RNA-based Therapies for Genetic Disorders
StartupSkip Therapeutics is a -based startup in the Health Tech & Life Sciences sector, established in 2021. RNA-based Therapies for Genetic Disorders. Skip Therapeutics was founded by Ariel Feiglin. Key investors include RMGP Biopharma Investment Fund, FutuRx, Israel Innovation Authority. The company has 1-10 employees. Core technologies: Biologicals, Molecules, Genes.
The company follows a B2B business model. Product stage: R&D.
- StageSeed
- ProductR&D
- ModelB2B
- Employees1-10
- HQ
- Last RoundUndisclosed
- RMGP Biopharma Investment Fund
- FutuRx
- Israel Innovation Authority
Ariel FeiglinCo-founder & CSO
What does Skip Therapeutics do?
Skip Therapeutics develops personalized RNA-based treatments for rare genetic diseases in directly identified patients and patient cohorts using a novel, proprietary computational engine. The companys bioinformatic pipeline analyzes disease-causing mutations and recognizes the best available molecular strategy to restore protein function using splice-modulating antisense oligonucleotides (ASOs). The analysis of mutation data at scale enables identification of treatable patient cohorts and optimizes target selection, with top candidates from the computational analyses experimentally validated and pursued for therapeutic development. Skip Therapeutics operates from the FutuRx biotech incubator.
Who founded Skip Therapeutics?
Skip Therapeutics was founded in 2021 by Ariel Feiglin (Co-founder & CSO).
What sector is Skip Therapeutics in?
Skip Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules, Genes. Target customers: Healthcare & Life Sciences, Life Sciences, Biotechnology.
Where is Skip Therapeutics located?
Skip Therapeutics is based in Ilan Ramon Street 2, Ness Ziona, Israel.